Lupin Ltd Q1 FY2026 Concall Summary

Key Takeaways

• A quarter of two halves: U.S. revenue hit its highest since Q4 FY2017 on the Tolvaptan exclusivity launch, while India formulations grew 8.6% in line with the market. Margins expanded 330 bps YoY despite a 151 bps step-up in R&D investment.
• Tolvaptan is the near-term needle-mover: The sole FTF launch contributed only a partial quarter, so the full run-rate benefit is still to come. Management expects the full contracted market share to reflect by the exit of Q2 or Q3.
• The FY27 growth bridge is already under construction: Complex generics, GLP-1s and biosimilars form the next wave, but the exact U.S. revenue trajectory depends on litigation outcomes and competitor entry timing that management did not quantify.
• Margins are a stated priority, not a promise: The company reaffirmed 24–25% EBITDA margin for FY26 and is "playing for continuous margin expansion," but declined to commit that FY27 margins would not dip versus FY26.
• What to watch next quarter: The pace of Tolvaptan share ramp, any update on additional tentative approvals for Tolvaptan, the Liraglutide launch in October, and whether the Pithampur observations escalate.

U.S. Business: The Tolvaptan Quarter

• Record revenue, partial contribution: U.S. revenues reached their highest level since Q4 FY2017, driven by the late-May launch of Tolvaptan with sole first-to-file exclusivity. The quarter captured only a few weeks of sales, so the full benefit is still ahead.
• Tolvaptan market dynamics: The product requires a Named Patient REMS program, which management believes makes substitution behaviour very different from a simple oral solid generic. No other tentative approvals are visible right now, and even if competitors arrive, the specialty channel and physician reluctance to switch stable patients should produce a longer tail.
• The offsetting drags: Additional generic competition in Albuterol, including Amphastar's entry, and low single-digit price erosion in base products partially offset the Tolvaptan contribution.
• Albuterol runway: Management sees at least 12–18 months of runway in Albuterol despite the new entrant.
• Tiotropium share-building: Commercial covered patient share is above 50%, but Medicare-Medicaid share is weaker. The team is working on offsetting patient costs in that segment and hopes share builds over the next couple of quarters.

Vinita Gupta: "Right now, there are no other tentative approvals on Tolvaptan, and it's a specialty product that requires a Named Patient REMS program, so we expect a substitution to be very different compared to a simple oral solid generic."

The Next Growth Wave: Complex Products, GLP-1s & Biosimilars

• Complex generics pipeline: The complex product pipeline targets brand sales of USD 150 billion, and management expects complex products to drive a significant portion of growth. Over 60 product filings are planned for the U.S. market alone in coming years.
• GLP-1 momentum: Lupin became the first Indian company to secure U.S. FDA approval of a GLP-1 product with generic Victoza (Liraglutide), launching by October. The approval was hard-won: the team navigated "pretty tricky queries," and management believes not every filer will reach the finish line, which could mean a more favourable competitive set than earlier expected.
• GLP-1 follow-on: Saxenda (Liraglutide) has a goal date into next year, and management hopes the FDA will expedite it now that Victoza is approved. Semaglutide injectable for India is targeted for end-FY26 via a partnership, with oral Semaglutide developed internally and expected in FY27.
• Biosimilars wave begins FY27: Pegfilgrastim approval is hoped for this year, with the Onpro device version filed and expected in FY27 or FY28. Ranibizumab has a June 2026 goal date and should reach market in FY27, building into FY28. Etanercept is expected in FY29, likely as one of four players, and remains a material product despite IRA-driven price erosion.
• Biosimilars strategy mirrors complex generics: The company targets first-wave positions with barriers to entry, exclusivity or semi-exclusivity, or leverages existing market positions in ophthalmology and respiratory.
• Respiratory biosimilars in development: Mepolizumab and Benralizumab are being developed, adding to the respiratory franchise depth.

Vinita Gupta: "We believe that it's fair to say Liraglutide was a complex product approval through the US FDA. The team really worked hard to respond to a number of pretty tricky queries and we believe that not everyone will get to the finish line."

India & Branded Markets

• India formulations grew 8.6% YoY, in line with IPM. Cardiac, GI and VMS therapies grew ahead of the market, while the diabetes segment was weighed down by loss of exclusivity on certain in-licensed brands.
• Chronic share steady at 65%: The in-licensed product share has dropped to 6.2% from roughly 12% in FY25, a deliberate shift that is positively impacting profitability as the company builds its own portfolio, including a novel pipeline.
• Respiratory franchise outperformance: The franchise grew 18.5% versus category growth of 12.2%, with MAT volume growth of 2.8%, double the IPM volume growth rate.
• India therapy expansion: The company is deepening its presence in GI, aiming to establish it as the fourth major therapy area, while also expanding in oncology and CNS. Over 80 product launches are planned in India over the next five years.
• Other developed markets: Growth was led by a 28% YoY increase in Europe, and management is optimistic about sustaining momentum behind a robust pipeline of complex and specialty products.
• Emerging markets mixed: Strong growth in South Africa offset tempered performance in LATAM and the Philippines.

Margins, Costs & Capital Allocation

• Margin walk (YoY): Gross margin improved 290 bps, driven by better product mix, input cost tailwinds, lower share of in-licensed products, increased volumes and other cost improvements. R&D investment rose 151 bps, and employee expenses grew 11.5% on annual increments and business growth. The net result was a 330 bps EBITDA margin expansion.
• FY26 margin commitment reaffirmed: Management reiterated the 24–25% EBITDA margin outlook for FY26, with R&D spend expected at roughly 8.5% of revenue for the full year.
• Adjacencies still a drag: The diagnostics, digital and API CDMO businesses remain loss-making, with an EBITDA impact close to 1%. Diagnostics is expected to reach breakeven next year.
• FY27 margin question left open: When asked whether FY27 margins could dip versus FY26, management said it is "playing for continuous margin expansion" but did not provide specific cost-saving targets or commit that margins would not dip.
• Capital allocation: The company continues to explore strategic allocation of capital for its long-term vision, including building a leading global specialty business through in-house innovation and selective acquisitions.

Ramesh Swaminathan: "The fact is we are playing for continuous margin expansion."

Pipeline Milestones & Regulatory Watchpoints

• Near-term launches: Glucagon launched yesterday. Liraglutide (generic Victoza) planned for October. Dalbavancin expected this year. Risperdal Consta has a September goal date, with launch hoped for the quarter after.
• Regulatory overhang at Pithampur: The Pithampur Unit-2 and Unit-3 sites received some observations in a Form 483. Management expressed confidence in addressing them and reaffirmed its commitment to full compliance, but the situation bears watching.
• Positive regulatory signal: Nagpur Unit-2 received an Establishment Inspection Report, a clean bill of health from the FDA.
• Dulera pathway: The company expects to respond to the CRL in FY26, with a U.S. launch hopefully by the second half of FY27 or early FY28. Management declined to disclose whether the CRL relates to clinical data or CMC queries.
• NaMuscla timeline pushed out: Patient recruitment for the Phase 3 study has been slow, and the company is opening new centres. The U.S. launch is now expected in FY29.
• Certolizumab: Clinical development will begin soon.

Guidance & Commitments

Key Metrics